Medlines

Medlines

Healthcare is changing at breakneck speed, and let's face it, staying informed is getting harder by the day. If only there were a way to get the industry news you need in less time than it takes to get prior auth approved. (Spoiler: There is.) Every Friday, start your day with Dr. Will Flanary (aka Dr. Glaucomflecken), Dr. Alok Patel, Dr. Jen Lincoln, Adam Rose, and Eva Johnson as they bring you the week's most important headlines across clinical care, health policy, groundbreaking publications, medical pop culture, and more. Presented with clear, unbiased, fact-first reporting made strictly for healthcare professionals, by healthcare professionals. Prepare to wow your colleagues with how informed you are, all without risking another evening doom-scrolling through 5% actual news and 95% videos of, well, if you know you know.  Medicine moves fast... So do we!  Learn More: www.medlinespod.com Medlines is A Human Content Production
00:00
00:00

Resumen del episodio

Friday, October 23, 2026 In today's episode, Dr. Alok Patel (@alokpatelmd) & Adam Rose (@adjoro) cover a phase three trial of nicotinamide riboside in early Parkinson disease. Over 52 weeks, the supplement boosted NAD metabolism but showed no clinical benefit, raising questions for NAD boosting strategies. They also walk through a large hospital comparison of phenobarbital and diazepam for alcohol withdrawal, with similar stays and ventilation rates and fewer self directed discharges on phenobarbital, and why diazepam protocols may stay the course pending randomized trials. Plus: they also discuss national measles trends, FDA warning letters to Amazon and Walmart, and more. Coverage Timeline: (00:00) Intro (01:05) NR Supplement Trial for Parkinson's (03:01) NAD Supplements & Influencer Hype (04:49) Phenobarbital vs. Diazepam (07:30) Measles Surge in US (08:27) New Sunscreen Ingredient BEMT (09:01) Blood Clots Have a story, think we missed something, want to say hi, or curious to learn about the Medlines…

Episodios

18-

Hospital Detox Shakeup and NFL Star Sidelined

Friday, October 23, 2026 In today's episode, Dr. Alok Patel (@alokpatelmd) & Adam Rose (@adjoro) cover a phase three trial of nicotinamide riboside in early Parkinson disease. Over 52 weeks, the supplement boosted NAD metabolism but showed no clinical benefit, raising questions for NAD boosting strategies. They also walk through a large hospital comparison of phenobarbital and diazepam for alcohol withdrawal, with similar stays and ventilation rates and fewer self directed discharges on phenobarbital, and why diazepam protocols may stay the course pending randomized trials. Plus: they also discuss national measles trends, FDA warning letters to Amazon and Walmart, and more. Coverage Timeline: (00:00) Intro (01:05) NR Supplement Trial for Parkinson's (03:01) NAD Supplements & Influencer Hype (04:49) Phenobarbital vs. Diazepam (07:30) Measles Surge in US (08:27) New Sunscreen Ingredient BEMT (09:01) Blood Clots Have a story, think we missed something, want to say hi, or curious to learn about the Medlines…

23 oct. 2026
17-

Schizophrenia Gets an App and Your Dog Is Losing Sleep

Friday, October 16, 2026 In today's episode, Dr. Alok Patel (@alokpatelmd) & Eva Johnson cover the FDA clearance of Motivista as the first prescription app for negative symptoms of schizophrenia. They break down the 16 week CONVOKE trial and what a 2.6 point edge over a control app means for stable patients on antipsychotics. They also review new ACP guidance placing menopausal hormone therapy first for hot flashes and night sweats, with second and third line options. Plus: they discuss early feasibility data on a medical AI chatbot for pre visit histories, new federal recommendations on concentrated kratom products, and more. Coverage Timeline: (00:00) Intro (01:08) Schizophrenia App Cleared (03:50) Hot Flashes Guidance (04:47) Dogs & Sleep Study (06:51) AI In Urgent Care (08:37) Awards & Dahlias Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode…

16 oct. 2026
16-

GLP-1 Shakeups and Airline Emergency Kit Upgrades

Friday, October 9, 2026 In today's episode, Dr. Will Flanary (@drglaucomflecken) & Adam Rose (@adjoro) cover Phase 3 results for retatrutide with up to 28.3% average weight loss at 80 weeks. They explain dosing, tolerability and what remains unproven for heart and kidney outcomes and how retatrutide compares with current GLP-1 options. They also break down a federal proposal to modernize airline emergency kits around nine life threatening categories with airline level discretion. Plus: they discuss a growing pediatric heart valve, the return of Doc, Best Medicine, Chicago Med and Grey’s Anatomy, and more. Coverage Timeline: (00:00) Intro (00:50) Retatrutide Weight Loss Trial (03:27) FAA Airline Medical Kits (06:56) Growing Heart Valve (07:26) Fasting Before Blood Work (08:18) Medical Drama Premieres Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit https://www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for…

09 oct. 2026
15-

The Future of Cancer Screening and... Horse Therapy?

Friday, October 2, 2026 In today's episode, Dr. Jennifer Lincoln (@drjenniferlincoln) joins Medlines as a new anchor! She and Eva Johnson cover an FDA advisory panel vote on an early cancer detection blood test for adults 50 and older. The panel called the test safe, then split on whether it works. The agency still has to rule. They also walk through a UCSF comparison of myomectomy and radiofrequency ablation for uterine fibroids. Both treatments improved symptoms over two years, and neither difference reached the study threshold for a clinically important advantage. Plus: new findings on animal therapy, and more. Coverage Timeline: (00:00) Intro (02:01) FDA Backs Multi-Cancer Blood Test (05:08) Uterine Fibroids: Surgery vs. Heat Therapy (07:47) Gambling ER Visits Surge (09:01) Miniature Horses Lift Teen Mood Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for…

02 oct. 2026
14-

Life with AI Scribes and Elizabeth Holmes Explained

Friday, September 25, 2026 In today's episode, Dr. Will Flanary (@drglaucomflecken) & Adam Rose (@Adjoro) cover new research on colonoscopy surveillance after high risk adenomas. A large randomized trial found that waiting five years instead of three led to nearly identical colorectal cancer rates. They explain what the interim results mean for screening guidance and what remains unanswered. Then they turn to a Washington court ruling on whether raw audio from an AI scribe counts as part of the medical record. Plus: they discuss Nathan Fielder’s documentary on Theranos founder Elizabeth Holmes, prenatal diet and food allergy risk, and more. Coverage Timeline: (0:00) Intro (0:54) Colonoscopy Intervals (3:55) AI Scribe Ruling (7:25) Theranos Doc (9:07) Conjoined Twins Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At:…

25 sep. 2026